PSNL

Business Context and Reporting Period

Company: Personalis, Inc. (PSNL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Personalis develops and sells advanced cancer genomic testing services for precision oncology, personalized testing, and population sequencing. The company operates a single facility in Fremont, California, and serves pharmaceutical companies, biopharmaceutical firms, diagnostic companies, and government entities (e.g., VA MVP).
Key Event: On July 20, 2026 (subsequent to the reporting period), the Company entered into an Agreement and Plan of Merger with Tempus AI, Inc. ("Tempus").

Key Financial Metrics

Note: YTD Gross Margin decline is driven by increased clinical diagnostic test costs where reimbursement amounts were less than the cost of testing services.

Material Changes vs. Prior Period

• Revenue Growth: Q2 2026 revenue increased 30% ($5.2M) compared to Q2 2025. This was driven by a 52% increase in Pharma testing services (primarily Merck) and a 442% increase in Clinical diagnostic revenue due to new Medicare coverage approvals.
• Revenue Declines: Enterprise sales dropped 100% due to the expiration of the Natera agreement. Population sequencing revenue decreased 9% due to planned lower volume from the VA MVP.
• Expense Increases:
  • Cost of Revenue: Increased 42% QoQ, primarily due to higher diagnostic test costs and direct material costs.
  • SG&A: Increased 55% QoQ, driven by higher Tempus sales/marketing fees ($3.8M vs $0.9M) and professional services related to the Merger Agreement.
  • R&D: Increased 32% QoQ due to higher personnel costs and lab supplies.
• Liquidity: Cash and cash equivalents decreased from $124.2M (Dec 31, 2025) to $94.0M (June 30, 2026). Net cash used in operating activities for the six months ended June 30, 2026, was $48.2M.

Guidance, Outlook, and Risks

Merger with Tempus AI

On July 20, 2026, Personalis entered into a definitive merger agreement with Tempus. Key terms include:

• Consideration: Shareholders will receive Tempus Class A Common Stock based on an exchange ratio. If the Tempus stock price is below $48.42, the ratio is fixed at 0.3356. If above, the ratio is $16.25 divided by the Tempus stock price.
• Cash Election: Tempus may elect to pay cash for up to 50% of the shares at $16.25 per share.
• Termination Fee: Personalis may be required to pay a termination fee of approximately $76.8 million under specific circumstances (e.g., change in recommendation or superior proposal).

Management Commentary & Outlook

• Reimbursement Milestones: The company secured Medicare coverage for NeXT Personal Dx for immunotherapy monitoring (late-stage solid tumors) and neoadjuvant therapy monitoring for breast cancer in Q2 2026.
• Capital Resources: Management believes current cash and short-term investments ($212.7M total) are sufficient to fund operations for at least the next 12 months. However, if the merger is not completed and cash is insufficient, the company may seek additional financing.
• ATM Facility: The company has an At-the-Market facility with approximately $145.4M remaining available, though sales are suspended while the merger is pending.

Risks and Contingencies

• Customer Concentration: Top three customers (Merck, VA MVP, Moderna) accounted for 67% of revenue in the first six months of 2026. Merck alone represented 30% of YTD revenue.
• Merger Uncertainty: Completion is subject to regulatory approvals (HSR Act), shareholder approval, and other conditions. Failure to close could result in significant costs and business disruption.
• Profitability: The company has a history of losses and expects to incur significant losses for the foreseeable future. Gross margins are volatile due to customer mix and reimbursement rates.
• Cybersecurity: In December 2025, a security incident involving a small number of user accounts and potential access to patient PHI was reported. No unauthorized access to financial systems was found.

Investor Verification Checklist

• Merger Status: Verify the progress of regulatory approvals and shareholder voting for the Tempus merger, as this is the primary catalyst for the stock.
• Reimbursement Sustainability: Confirm the actual volume uptake of NeXT Personal Dx following the new Medicare coverage approvals for immunotherapy and breast cancer monitoring.
• Customer Concentration: Monitor the renewal status and volume commitments of the top three customers (Merck, VA MVP, Moderna), which drive the majority of revenue.
• Cash Burn Rate: Assess the runway of the $212.7M in liquid assets against the current operating cash burn of ~$48M per six months, especially if the merger faces delays.
• Gross Margin Trajectory: Evaluate whether the company can improve gross margins as clinical diagnostic volumes scale, given the current negative margin on some diagnostic tests.